Health Care·Pharmaceuticals·$547.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.15 | N/A | +2.95% |
management commentary, guidance changes, and full analysis available with Pro.
| +2.95% |
Tone: Cautiously Optimistic
Overall, management conveyed a positive outlook despite not providing specific guidance. They emphasized the importance of innovation and market adaptability.
Management expressed confidence in the company's long-term growth potential.
They highlighted ongoing investments in research and development.
This earnings report indicates that Johnson & Johnson is performing slightly better than expected in terms of earnings per share. However, the lack of revenue data and guidance may leave investors uncertain about future performance. The stock reaction is not available, but the positive EPS surprise suggests some level of investor confidence.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
GOLDMAN SACHS GROUP
Jul 14, 2009